VitalFlo, a healthcare startup based in Portland Oregon, has developed a solution to help doctors measure, monitor, and predict their patients’ lung health. The company recently raised $757,228 in funding, demonstrating the growing interest in digital health solutions that can improve patient outcomes and reduce healthcare costs.
VitalFlo was founded in 2022 by Luke Marshall and Andy Taylor, who recognized the need for a more efficient and accurate way to diagnose and manage respiratory illnesses. The company’s flagship product, the VitalFlo Respiratory Monitor, is a handheld device that measures lung function using a combination of hardware and software.
The Respiratory Monitor is designed to be used in both clinical and home settings, making it a versatile tool for doctors and patients alike. The device measures a patient’s forced expiratory volume in one second (FEV1), which is a standard measure of lung function. FEV1 is used to diagnose and monitor respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
The Monitor uses a patented algorithm that combines data from the device’s sensors with a patient’s demographic and clinical information to provide a more accurate assessment of lung function. The device is easy to use and requires minimal training, making it a practical tool for healthcare providers.
To use the device, a patient simply blows into the VitalFlo Respiratory Monitor for six seconds. The device then measures the patient’s FEV1 and transmits the data to a secure cloud server. The data can be accessed by the patient’s healthcare provider using a secure web-based platform, allowing for real-time monitoring and early intervention if necessary.
The technology offers several benefits to both patients and healthcare providers. For patients, the device provides a more accurate assessment of lung function than traditional spirometry tests, which can be time-consuming and require specialized equipment. The device is also easy to use, making it a practical tool for patients to monitor their lung health at home.
For healthcare providers, the device provides real-time data that can be used to monitor patients’ lung function and identify potential issues before they become severe. The device also allows for remote monitoring, reducing the need for in-person visits and potentially lowering healthcare costs.
VitalFlo’s technology has the potential to transform the way respiratory illnesses are diagnosed and managed. By providing more accurate and timely data, the device can help healthcare providers make better-informed decisions and improve patient outcomes.
The device can also help reduce healthcare costs by allowing for remote monitoring and early intervention. By identifying potential issues before they become severe, healthcare providers can prevent hospitalizations and other costly interventions.
VitalFlo’s technology is particularly relevant in the current healthcare landscape, which has been heavily impacted by the COVID-19 pandemic. Respiratory illnesses such as COVID-19 can cause significant lung damage, and the VitalFlo Respiratory Monitor can help healthcare providers monitor and manage patients’ lung function during and after the illness.
You can also check How Swell helps customers save one billion dollars in credit card interest.
VitalFlo’s recent fundraising success is a testament to the growing interest in digital health solutions that can improve patient outcomes and reduce healthcare costs. The company raised $757,228 in a recent funding round led by the crowdfunding platform, Wefunder.
The funding will be used to expand VitalFlo’s sales and marketing efforts and further develop its technology. The company has also announced plans to expand its product line to include additional respiratory health solutions.
VitalFlo’s technology offers a practical and efficient solution for measuring, monitoring, and predicting patients’ lung health